# Cellular Biomedicine Group

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cellular-biomedicine-group

- Industry: Biotechnology
- Headquarters: Rockville, US
- Website: www.cellbiomedgroup.com
- Total disclosed funding: $120M
- Latest round: Series A (Sep 29, 2021)
- Investors on record: 5

## About

Based in the US, Cellular Biomedicine Group, Inc. focuses on developing innovative immune-oncology therapies, particularly utilizing advanced cellular technologies to treat cancers and immunological disorders.Cellular Biomedicine Group, Inc. operates in the biopharmaceutical sector, developing therapies for cancer treatment. Founded in 2009 in Rockville, US, the company has undergone several funding rounds, with notable backers such as Astra Zeneca CICC Healthcare Venture Capital Fund and Sequoia Capital. CEO Tony Liu leads the organization, which has raised a total of USD 120.00 mn, primarily through its most recent Series A funding round in September 2021, supporting its focus on immune-oncology solutions.Cellular Biomedicine Group, Inc. specializes in developing T cell-based therapeutics, including Chimeric Antigen Receptor T cell (CAR-T) therapies and Tumor Infiltrating Lymphocytes (TIL) aimed at treating various cancers and immunological conditions. These products are designed to enhance immune responses against malignancies and are marketed primarily to hospitals, oncology clinics, and academic medical centers in North America and Europe.In the most recent reporting year, 2019, Cellular Biomedicine Group, Inc. reported revenues of USD 339,920, with an EBITDA of USD -45,353,881, reflecting the financial dynamics typical in early-stage biopharmaceutical companies.Following the recent Series A funding round completed on 2021-09-29, which raised USD 120.00 mn, Cellular Biomedicine Group, Inc. aims to accelerate the clinical development of its immune-oncology platform. This includes advancements in therapies involving C-CAR039 and C-CAR088, along with armored CAR-T and TIL therapies targeting solid tumors. The funding will also support the further development of its stem cell platform, as the company explores expansion into new markets to enhance its global presence.

## Funding rounds

- Series A, Sep 29, 2021, $120M — Hong Shan, GIC, YF Capital, TF Capital, Astra Zeneca CICC Healthcare Venture Capital Fund

## Investors

- Hong Shan — Series A
- GIC — Series A
- YF Capital (https://capitalatlas.ai/funds/yf-capital) — Series A
- TF Capital — Series A
- Astra Zeneca CICC Healthcare Venture Capital Fund — Series A